The safety, tolerability, and pharmacodynamics of Lumacaftor as monotherapy was evaluated in adult patients with CF, homozygous for the F508del-CFTR, in a 4-week, double-blind RCT (NCT00865904) [33]. The gene discussed is CFTR; the disease is cystic fibrosis.